Literature DB >> 19524584

Sex-specific therapeutic strategies based on neuroactive steroids: In search for innovative tools for neuroprotection.

Roberto Cosimo Melcangi1, Luis Miguel Garcia-Segura.   

Abstract

Different pathologies of the central and peripheral nervous system show sex differences in their incidence, symptomatology and/or neurodegenerative outcome. These include Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple sclerosis, traumatic brain injury, stroke, autism, schizophrenia, depression, anxiety disorders, eating disorders and peripheral neuropathy. These sex differences reveal the need for sex-specific neuroprotective strategies. This review article and other manuscripts published in this issue of Hormones and Behavior analyze possible sex-specific therapeutic strategies based on neuroactive steroids. In particular in our introductory article, the possibility that sex differences in the levels or in the action of neuroactive steroids may represent causative factors for sex differences in the incidence or manifestation of pathologies of the nervous system is considered. 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19524584     DOI: 10.1016/j.yhbeh.2009.06.001

Source DB:  PubMed          Journal:  Horm Behav        ISSN: 0018-506X            Impact factor:   3.587


  16 in total

Review 1.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

2.  Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiology of Parkinson's disease.

Authors:  Roberto Cosimo Melcangi; Donatella Caruso; Giovanna Levandis; Federico Abbiati; Marie-Therese Armentero; Fabio Blandini
Journal:  J Mol Neurosci       Date:  2011-06-14       Impact factor: 3.444

Review 3.  Role of estrogen treatment in the management of schizophrenia.

Authors:  Jayashri Kulkarni; Emmy Gavrilidis; Roisin Worsley; Emily Hayes
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 4.  Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines.

Authors:  Glenda E Gillies; Simon McArthur
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 5.  Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?

Authors:  Silvia Giatti; Silvia Diviccaro; Giancarlo Panzica; Roberto Cosimo Melcangi
Journal:  Endocrine       Date:  2018-04-19       Impact factor: 3.633

Review 6.  Liver X receptors, nervous system, and lipid metabolism.

Authors:  G Cermenati; E Brioschi; F Abbiati; R C Melcangi; D Caruso; N Mitro
Journal:  J Endocrinol Invest       Date:  2013-04-18       Impact factor: 4.256

7.  Age-related changes in neuroactive steroid levels in 3xTg-AD mice.

Authors:  Donatella Caruso; Anna M Barron; Meghan A Brown; Federico Abbiati; Paloma Carrero; Christian J Pike; Luis M Garcia-Segura; Roberto C Melcangi
Journal:  Neurobiol Aging       Date:  2012-11-02       Impact factor: 4.673

8.  Sex differences in the inflammatory response of primary astrocytes to lipopolysaccharide.

Authors:  María Santos-Galindo; Estefanía Acaz-Fonseca; María J Bellini; Luis M Garcia-Segura
Journal:  Biol Sex Differ       Date:  2011-07-11       Impact factor: 5.027

9.  Gender effect on neurodegeneration and myelin markers in an animal model for multiple sclerosis.

Authors:  Alessandro Massella; Giulia D'Intino; Mercedes Fernández; Sandra Sivilia; Luca Lorenzini; Silvia Giatti; Roberto C Melcangi; Laura Calzà; Luciana Giardino
Journal:  BMC Neurosci       Date:  2012-01-24       Impact factor: 3.288

10.  The role of oestrogen and other hormones in the pathophysiology and treatment of schizophrenia.

Authors:  Emily Hayes; Emorfia Gavrilidis; Jayashri Kulkarni
Journal:  Schizophr Res Treatment       Date:  2012-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.